Hi there!
We track 70,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Arctoris
Arctoris accelerates drug discovery by generating high‑quality, reproducible experimental data to improve decision-making and speed programs toward the clinic. It operates as a drug discovery…
Arctoris
Arctoris accelerates drug discovery by generating high‑quality, reproducible experimental data to improve decision-making and speed programs toward the clinic. It operates as a drug discovery…
TL;DR
What they do: Technology-enabled drug discovery services using the Ulysses automated wet-lab platform
Headquarters: Oxford (UK) and Boston (US)
Founded: 2016
Founders / Leadership: Tom (Thomas A.) Fleming (co-founder, CEO) and Martin-Immanuel Bittner (co-founder)
Latest disclosed funding: Seed round closed 2019 (approx. $8M / £3.2M)
Company Overview
Problem Domain
Drug discovery R&D — target validation, hit finding, hit-to-lead and lead optimization through automated experimental data generation.
Founded
2016
Industry
Biotechnology
Tech Stack
Funding Track Record
$8M
Publicly disclosed seed round closed in 2019 (also reported as £3.2M in some disclosures).
Investor Signal
“Acequia Capital; Alexander Straub; Charlie Songhurst; Eurostars; Formic Ventures; Future Planet Capital; Mark Evans; Patrick Pichette; TD Veen; Tanarra Capital; Vishal Gulati”